Antiepileptic effects of NPY on pentylenetetrazole seizures

Regulatory Peptides

Volumn 75-76, Issue , 1998, Pages 279-282

  Woldbye, David P d ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anticonvulsant; Epilepsy; Inhibition; Neuropeptide Y; PTZ

Indexed keywords

NEUROPEPTIDE Y; PENTETRAZOLE;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; TONIC SEIZURE;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPEPTIDE Y; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; SEIZURES;

EID: 0032566849     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00079-2     Document Type: Article

References (25)

1. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 381:1996;415-418.
2. Baraban S.C., Hollopeter G., Erickson J.C., Schwartzkroin P.A., Palmiter R.D. Knockout mice reveal a critical anti-epileptic role for neuropeptide Y. J Neurosci. 17:1997;8927-8936.
3. Woldbye D.P.D., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat. Med. 3:1997;761-764.
4. Woldbye D.P.D., Madsen T.M., Larsen P.J., Mikkelsen J.D., Bolwig T.G. Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res. 737:1996;162-168.
5. Colmers W.F., Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 17:1994;373-379.
6. Klapstein G.J., Colmers W.F. Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J Neurophysiol. 78:1997;1651-1661.
7. Smialowska M., Bijak M., Sopala M., Tokarski K. Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study. Neuropeptides. 30:1996;7-12.
8. Sperk G. Kainic acid seizures in the rat. Prog Neurobiol. 42:1994;1-32.
9. Ben-Ari Y., Tremblay E., Riche D., Ghilini G., Naquet R. Electrographic, clinical and pathological alterations following systemic administration of kainic acid, bicuculline or pentetrazole: Metabolic mapping using the deoxyglucose method with special reference to the pathology of epilepsy. Neuroscience. 6:1981;1361-1391.
10. Swinyard E.A. Laboratory assay of clinically effective antiepileptic drugs. J Am Pharm Assoc. 38:1949;201-204.
11. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs III. Pentylenetetrazole seizure models. Epilepsy Res. 8:1991;171-189.
12. Siegel S, Castellan NJ Jr. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill, 1988.
13. Blomqvist A.G., Herzog H. Y-receptor subtypes - how many more? Trends Neurosci. 20:1997;294-298.
14. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., Weinshank R.L. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature. 382:1996;168-171.
15. MacDonald R.L., Barker J.L. Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Nature. 267:1977;720-721.
16. Ramanjaneyulu R., Ticku M.J. Interactions of pentamethylenetetrazole and tetrazole analogues with the picrotoxinin site of the benzodiazepine-GABA receptor-ionophore complex. Eur J Pharmacol. 98:1984;337-345.
17. Squires R.F., Saedrup E., Crawley J.N., Skolnick P., Paul S.M. Convulsant potencies of tetrazoles are highly correlated with actions on GABA/benzodiazepine/picrotoxin receptor complexes in brain. Life Sci. 35:1984;1439-1444.
18. Nevins M.E., Arnolde S.M. A comparison of the anticonvulsant effects of competitive and non-competitive antagonists of the N-methyl-D-aspartate receptor. Brain Res. 503:1989;1-4.
19. Sonnenberg J.L., Mitchelmore C., Macgregor-Leon P.F., Hempstead J., Morgan J.I., Curran T. Glutamate receptor agonists increase the expression of Fos, Fra, and AP-1 DNA binding activity in the mammalian brain. J Neurosci Res. 24:1989;72-80.
20. Castillo P.E., Malenka R.C., Nicoll R.A. Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature. 388:1997;182-186.
21. Jensen F.E., Firkusny I.R., Mower G.D. Differences in c-fos immunoreactivity due to age and mode of seizure induction. Mol Brain Res. 17:1993;185-193.
22. Le Gal La Salle G. Long-lasting and sequential increase of c-fos oncoprotein expression in kainic acid-induced status epilepticus. Neurosci Lett. 88:1988;127-130.
23. MacLean P.D. Chemical and electrical stimulation of hippocampus in unrestrained animals. AMA Arch Neurol Psychiatr. 78:1957;128-142.
24. Barnes M.I., Mitchell C.L. Differential effects of colchicine lesions of dentate granule cells on wet dog shakes and seizures elicited by direct hippocampal stimulation. Physiol Behav. 48:1990;131-138.
25. Mitchell C.L., Grimes L.M., Hong J.S. Granule cells in the ventral dentate gyrus are essential for kainic acid-induced wet dog shakes but not those induced by precipitated abstinence in morphine-dependent rats. Brain Res. 511:1990;338-340.